Latest Insider Transactions at Agios Pharmaceuticals, Inc. (AGIO)
This section provides a real-time view of insider transactions for Agios Pharmaceuticals, Inc. (AGIO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of AGIOS PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of AGIOS PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 14
2024
|
James William Burns Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
545
-1.69%
|
$13,625
$25.14 P/Share
|
|
Feb 14
2024
|
Sarah Gheuens Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
642
-1.88%
|
$16,050
$25.14 P/Share
|
|
Feb 12
2024
|
Theodore James Washburn Jr. Principal Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
777
+18.09%
|
-
|
|
Feb 12
2024
|
James William Burns Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,833
+5.38%
|
-
|
|
Feb 12
2024
|
Sarah Gheuens Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,162
+5.97%
|
-
|
|
Jan 24
2024
|
James William Burns Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,708
-5.32%
|
$35,868
$21.64 P/Share
|
|
Jan 24
2024
|
Brian Goff Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
7,635
-13.38%
|
$160,335
$21.64 P/Share
|
|
Jan 24
2024
|
Jacqualyn A Fouse Director |
SELL
Open market or private sale
|
Direct |
10,722
-7.66%
|
$225,162
$21.64 P/Share
|
|
Jan 24
2024
|
Cecilia Jones Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,886
-12.61%
|
$39,606
$21.64 P/Share
|
|
Jan 24
2024
|
Sarah Gheuens Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,708
-5.08%
|
$35,868
$21.64 P/Share
|
|
Jan 24
2024
|
Tsveta Milanova Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,618
-10.89%
|
$33,978
$21.64 P/Share
|
|
Jan 20
2024
|
James William Burns Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,750
+15.2%
|
-
|
|
Jan 20
2024
|
Brian Goff Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,018
+22.97%
|
-
|
|
Jan 20
2024
|
Jacqualyn A Fouse Director |
BUY
Exercise of conversion of derivative security
|
Direct |
23,900
+14.58%
|
-
|
|
Jan 20
2024
|
Cecilia Jones Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,380
+26.46%
|
-
|
|
Jan 20
2024
|
Sarah Gheuens Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,750
+14.61%
|
-
|
|
Jan 20
2024
|
Tsveta Milanova Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,448
+26.84%
|
-
|
|
Jan 09
2024
|
James William Burns Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,163
-4.23%
|
$25,586
$22.99 P/Share
|
|
Jan 09
2024
|
Jacqualyn A Fouse Director |
SELL
Open market or private sale
|
Direct |
8,391
-6.74%
|
$184,602
$22.99 P/Share
|
|
Jan 09
2024
|
Brian Goff Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
12,066
-23.15%
|
$265,452
$22.99 P/Share
|
|
Jan 09
2024
|
Sarah Gheuens Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,789
-6.03%
|
$39,358
$22.99 P/Share
|
|
Jan 05
2024
|
James William Burns Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,250
+10.57%
|
-
|
|
Jan 05
2024
|
Jacqualyn A Fouse Director |
BUY
Exercise of conversion of derivative security
|
Direct |
17,500
+12.33%
|
-
|
|
Jan 05
2024
|
Brian Goff Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,527
+32.88%
|
-
|
|
Jan 05
2024
|
Sarah Gheuens Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+14.43%
|
-
|
|
Jan 05
2024
|
Tsveta Milanova Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,902
-23.58%
|
$63,844
$22.32 P/Share
|
|
Jan 03
2024
|
Tsveta Milanova Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,475
+40.78%
|
-
|
|
Sep 28
2023
|
Cecilia Jones Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,179
-18.54%
|
$52,296
$24.79 P/Share
|
|
Sep 26
2023
|
Cecilia Jones Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,472
+38.86%
|
-
|
|
Aug 17
2023
|
James William Burns Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
6,395
-21.12%
|
$166,270
$26.28 P/Share
|
|
Aug 11
2023
|
Rahul D. Ballal Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,302
+50.0%
|
-
|
|
Aug 11
2023
|
Cynthia Smith Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,302
+50.0%
|
-
|
|
Aug 09
2023
|
Kaye I Foster Cheek Director |
SELL
Open market or private sale
|
Direct |
25,000
-68.45%
|
$625,000
$25.96 P/Share
|
|
Aug 09
2023
|
Kaye I Foster Cheek Director |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+40.63%
|
$450,000
$18.09 P/Share
|
|
Aug 08
2023
|
Brian Goff Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
10,178
-27.68%
|
$254,450
$25.48 P/Share
|
|
Aug 08
2023
|
Brian Goff Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,691
+38.16%
|
-
|
|
Aug 07
2023
|
Theodore James Washburn Jr. Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,918
-51.56%
|
$72,950
$25.39 P/Share
|
|
Aug 01
2023
|
Theodore James Washburn Jr. Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,232
-17.88%
|
$32,032
$26.26 P/Share
|
|
Aug 01
2023
|
Theodore James Washburn Jr. Principal Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,150
+37.59%
|
-
|
|
Jun 30
2023
|
Brian Goff Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
11,449
-44.85%
|
$320,572
$28.36 P/Share
|
|
Jun 30
2023
|
Sarah Gheuens Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,707
-6.6%
|
$47,796
$28.36 P/Share
|
|
Jun 30
2023
|
Jacqualyn A Fouse Director |
SELL
Open market or private sale
|
Direct |
10,718
-9.11%
|
$300,104
$28.36 P/Share
|
|
Jun 30
2023
|
James William Burns Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,707
-5.34%
|
$47,796
$28.36 P/Share
|
|
Jun 30
2023
|
Tsveta Milanova Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,618
-29.69%
|
$45,304
$28.36 P/Share
|
|
Jun 30
2023
|
Cecilia Jones Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,597
-29.68%
|
$44,716
$28.36 P/Share
|
|
Jun 28
2023
|
Brian Goff Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,528
+50.0%
|
-
|
|
Jun 28
2023
|
Sarah Gheuens Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,750
+18.19%
|
-
|
|
Jun 28
2023
|
Jacqualyn A Fouse Director |
BUY
Exercise of conversion of derivative security
|
Direct |
23,900
+16.88%
|
-
|
|
Jun 28
2023
|
James William Burns Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,750
+15.24%
|
-
|
|
Jun 28
2023
|
Tsveta Milanova Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,449
+50.0%
|
-
|